Tesaro Adds Runway By Out-licensing Niraparib In Prostate Cancer

Deriving income from letting somebody else pursue a direction you weren't prioritizing is always a good business strategy, which is what Tesaro Inc. did by out-licensing niraparib in prostate cancer to Janssen Biotech Inc. while retaining all other rights to the poly ADP-ribose polymerase (PARP) inhibitor.